AI Stock Memo: KTTA - Pasithea Therapeutics - RankAlpha

KTTA

Rating neutralAI Memo

Pasithea Therapeutics

As of 2026-07-15/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-07-15 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

6‑12m

Key catalyst

Q4 2026 interim NF1 data update • 2026-12-31

Expected move: -7%

Biggest risk

The evidence remains interim Phase 1 data from small, non-randomized studies; efficacy durability, dose selection, regulatory path, and eventual financing remain unresolved.

Invalidation

Break below $0 or thesis failure.

What would change my mind?

Q4 NF1 data could validate dose selection and clinical activity, while the advanced-cancer program's tolerability and durable stable-disease observations preserve optionality for PAS-004.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-07-15

Base target

p=55%

Bull target

p=20%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Financing and runway checkpoint
Follow-on PAS-004 advanced-cancer dataset
Q4 NF1 data could validate dose selection and clinical activity, while the advanced-cancer program's tolerability and durable stable-disease observations preserve optionality for PAS-004.

BearKey bullets

Dose escalation is ongoing and the maximum tolerated dose has not been established.
Future data may be negative, ambiguous, or less durable than current observations.
Low coverage, limited liquidity, and loose peer comparability increase price volatility and reduce confidence in consensus valuation.

WatchKey bullets

Q4 2026 interim NF1 data update

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $0 (p=55%)

Bull/Bear spread: +128% / -63%

Vs latest close: Bull +128% · Base -7% · Bear -63%

Scenario probabilities

Bull Target: $1 (p=20%)Base Target: $0 (p=55%)Bear Target: $0 (p=25%)

Commentary

Primary-source company updates are constructive on tolerability, NF1 study expansion, and upcoming Q4 2026 data, but the stock remained near $0.48 as of 2026-07-14. There is no usable social or analyst-revision signal in the packet, so the positive clinical narrative should be treated as a monitoring hook rather than a confirmed rerating thesis.

As of 2026-07-15 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Q4 NF1 data could validate dose selection and clinical activity, while the advanced-cancer program's tolerability and durable stable-disease observations preserve optionality for PAS-004.

Bear Case

The evidence remains interim Phase 1 data from small, non-randomized studies; efficacy durability, dose selection, regulatory path, and eventual financing remain unresolved.

Drivers

Scannable catalysts and supporting factors

Financing and runway checkpoint
Follow-on PAS-004 advanced-cancer dataset

Scenarios

Bull Target (Scenario probability)

$1 / p=20% prob

Base Target (Scenario probability)

$0 / p=55% prob

Bear Target (Scenario probability)

$0 / p=25% prob

Price $0 as of 2026-07-14

Nearest Scenario: Base (∆ 7%)

Targets vs latest close: Bull +128% · Base -7% · Bear -63%

Sentiment & Exposure

News Sentiment (30d)

0.25

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
Q4 2026 interim NF1 data update
The Phase 1/1b NF1 study has enrolled and dosed 18 patients; protocol amendments added higher doses, longer treatment, and expanded imaging, with an interim data update targeted for Q4 2026 [#IR-2026-06-16].
Prob 60.00% • Move 55.00% • Priced-in 30.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Financing and runway checkpoint
2027-05-15
The company remains development-stage and expects significant additional capital to fund clinical development, creating a recurring dilution and financing overhang despite near-term liquidity support [#SEC-10K-2026-03-30] [#SEC-10Q-2026-05-15].
Prob 70% • Move -15% • Priced-in 55%
Follow-on PAS-004 advanced-cancer dataset
2027-07-15
June 2026 interim data reported 34 patients dosed, no dose-limiting toxicities, Grade 1–2 treatment-related adverse events, and durable stable disease in some heavily pretreated patients. Dose escalation continues, with a larger dataset planned for a future scientific conference [#IR-2026-06-30].
Prob 50% • Move 35% • Priced-in 40%

Risks

Dose escalation is ongoing and the maximum tolerated dose has not been established.
Future data may be negative, ambiguous, or less durable than current observations.
Low coverage, limited liquidity, and loose peer comparability increase price volatility and reduce confidence in consensus valuation.
Small, early-stage clinical datasets may not translate into meaningful efficacy or registrational evidence.
The company expects significant additional capital for development, creating dilution and financing risk [#SEC-10K-2026-03-30].

Peers

Symbol	Summary
CYCN	Same-sector microcap biotech comparator; useful mainly for financing and clinical-event volatility context, with no confirmed indication overlap.
GTBP	Loose same-sector microcap comparator; relevant for development-stage execution and capital-markets risk rather than direct PAS-004 read-through.
HOWL	Small-cap biotech comparator with event-driven development risk; peer fit is limited and should not drive valuation conclusions.
PTN	Same-sector market-cap comparator; useful for broad microcap biotech sentiment and financing context, not a close clinical peer.
TPST	Same-sector microcap comparator; relevant for trial-driven volatility but indication comparability is unconfirmed.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-07-15